Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On August8, 2017, Aquinox Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the second quarter ended June30, 2017. The full text of the press release announcing such results is attached as Exhibit99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this current report on Form 8-K and the press release attached as Exhibit 99.1 hereto is being furnished, but shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
| Item 2.02. | Financial Statements and Exhibits. |
(d) Exhibits
|
Number |
Description |
| 99.1 | Press Release of Aquinox Pharmaceuticals, Inc. dated August8, 2017 |
AQUINOX PHARMACEUTICALS, INC ExhibitEX-99.1 2 d439391dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 For Immediate Release Aquinox Pharmaceuticals Announces Second Quarter 2017 Financial Results – Conference call update today at 8:30AM ET – Vancouver,…To view the full exhibit click here
About Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP)
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology. Its primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells. The Company’s product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. It has completed and reported results from its Leadership trial, which is a multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial.